Mr. Muiris O'Connor:

We can contribute to the formulation of the European positions but we will have to live with the settlement. One of the key things we want is that it settles in a reasonably short space of time and the industry operating throughout Europe has a clear understanding of the parameters. As Deputy Cullinane knows, we have a very strong genetic pharmaceutical industry that has an interest quite contrary to the new drug developers. The genetic pharmaceutical industry has an interest in shortening the period and then the production at scale of drugs that prove effective in genetic format.